UCB SA (UCBJF)
USD 150.7
(0.0%)
USD 150.7
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.27 Billion EUR | -13.01% |
| 2022 | 3.84 Billion EUR | -11.45% |
| 2021 | 4.33 Billion EUR | 8.91% |
| 2020 | 3.98 Billion EUR | 9.3% |
| 2019 | 3.64 Billion EUR | 6.14% |
| 2018 | 3.43 Billion EUR | 3.12% |
| 2017 | 3.33 Billion EUR | 11.9% |
| 2016 | 2.97 Billion EUR | 9.45% |
| 2015 | 2.71 Billion EUR | 18.68% |
| 2014 | 2.29 Billion EUR | -0.26% |
| 2013 | 2.29 Billion EUR | -3.41% |
| 2012 | 2.37 Billion EUR | 6.49% |
| 2011 | 2.23 Billion EUR | 3.14% |
| 2010 | 2.16 Billion EUR | 3.54% |
| 2009 | 2.09 Billion EUR | -14.83% |
| 2008 | 2.45 Billion EUR | -4.81% |
| 2007 | 2.57 Billion EUR | 30.12% |
| 2006 | 1.98 Billion EUR | 10.66% |
| 2005 | 1.79 Billion EUR | -31.28% |
| 2004 | 2.6 Billion EUR | 8.7% |
| 2003 | 2.39 Billion EUR | -24.58% |
| 2002 | 3.17 Billion EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 970 Million EUR | -41.35% |
| 2024 Q2 | 970 Million EUR | 0.0% |
| 2023 Q3 | 879 Million EUR | -47.93% |
| 2023 Q1 | 858.5 Million EUR | -48.5% |
| 2023 FY | 3.34 Billion EUR | -13.01% |
| 2023 Q4 | 1.65 Billion EUR | 88.17% |
| 2023 Q2 | 1.68 Billion EUR | 96.62% |
| 2022 Q4 | 1.66 Billion EUR | 0.0% |
| 2022 Q2 | 1.98 Billion EUR | 97.71% |
| 2022 Q1 | 1 Billion EUR | -53.47% |
| 2022 FY | 3.84 Billion EUR | -11.45% |
| 2021 FY | 4.33 Billion EUR | 8.91% |
| 2021 Q4 | 2.16 Billion EUR | 92.0% |
| 2021 Q3 | 1.12 Billion EUR | -43.89% |
| 2021 Q2 | 2 Billion EUR | 91.96% |
| 2021 Q1 | 1.04 Billion EUR | -46.87% |
| 2020 Q2 | 1.84 Billion EUR | 91.48% |
| 2020 Q4 | 1.96 Billion EUR | 90.97% |
| 2020 Q1 | 962.5 Million EUR | -47.69% |
| 2020 FY | 3.98 Billion EUR | 9.3% |
| 2020 Q3 | 1.02 Billion EUR | -44.14% |
| 2019 Q4 | 1.84 Billion EUR | 0.0% |
| 2019 FY | 3.64 Billion EUR | 6.14% |
| 2019 Q1 | 862.5 Million EUR | 0.0% |
| 2019 Q2 | 1.64 Billion EUR | 90.84% |
| 2018 Q2 | 848 Million EUR | 0.0% |
| 2018 FY | 3.43 Billion EUR | 3.12% |
| 2018 Q1 | 848 Million EUR | 1.92% |
| 2017 FY | 3.33 Billion EUR | 11.9% |
| 2017 Q2 | 805 Million EUR | 0.0% |
| 2017 Q1 | 805 Million EUR | 5.85% |
| 2017 Q4 | 832 Million EUR | 0.0% |
| 2017 Q3 | 832 Million EUR | 3.35% |
| 2016 Q1 | 712 Million EUR | 5.48% |
| 2016 FY | 2.97 Billion EUR | 9.45% |
| 2016 Q3 | 760.5 Million EUR | 6.81% |
| 2016 Q4 | 760.5 Million EUR | 0.0% |
| 2016 Q2 | 712 Million EUR | 0.0% |
| 2015 Q4 | 675 Million EUR | 0.0% |
| 2015 Q1 | 684.5 Million EUR | 15.24% |
| 2015 Q2 | 684.5 Million EUR | 0.0% |
| 2015 Q3 | 675 Million EUR | -1.39% |
| 2015 FY | 2.71 Billion EUR | 18.68% |
| 2014 Q1 | 551.5 Million EUR | 7.19% |
| 2014 Q3 | 594 Million EUR | 7.71% |
| 2014 Q2 | 551.5 Million EUR | 0.0% |
| 2014 Q4 | 594 Million EUR | 0.0% |
| 2014 FY | 2.29 Billion EUR | -0.26% |
| 2013 Q3 | 514.5 Million EUR | -9.66% |
| 2013 Q1 | 569.5 Million EUR | 0.0% |
| 2013 FY | 2.29 Billion EUR | -3.41% |
| 2013 Q4 | 514.5 Million EUR | 0.0% |
| 2013 Q2 | 569.5 Million EUR | 0.0% |
| 2012 FY | 2.37 Billion EUR | 6.49% |
| 2011 FY | 2.23 Billion EUR | 3.14% |
| 2010 FY | 2.16 Billion EUR | 3.54% |
| 2009 FY | 2.09 Billion EUR | -14.83% |
| 2008 FY | 2.45 Billion EUR | -4.81% |
| 2007 FY | 2.57 Billion EUR | 30.12% |
| 2006 FY | 1.98 Billion EUR | 10.66% |
| 2005 FY | 1.79 Billion EUR | -31.28% |
| 2004 FY | 2.6 Billion EUR | 8.7% |
| 2003 FY | 2.39 Billion EUR | -24.58% |
| 2002 FY | 3.17 Billion EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | -33944.324% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 2633479.208% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -2647.096% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1024177.72% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 6780182.472% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 134153441.533% |
| BioStem Technologies, Inc. | 15.42 Million USD | -21112.528% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1853094.382% |
| CSL Limited | 7.56 Billion USD | 56.725% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 12783.154% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -27851.478% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2328725.623% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -21714.788% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -105480235.268% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -33308.209% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -4977991.529% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 9581359.151% |
| Mesoblast Limited | -35.16 Million USD | 9403.913% |
| Marizyme, Inc. | 457.7 Thousand USD | -714775.618% |
| Genus plc | 178.7 Million USD | -1731.002% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -1386.57% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -5258152.178% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -797627.744% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 29745554.545% |
| ContraFect Corporation | -154 Thousand USD | 2124775.325% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 6544100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -4262481.259% |
| IMV Inc. | -962.29 Thousand USD | 340119.412% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 844484.918% |
| MultiCell Technologies, Inc. | 49.32 USD | -6634225366.342% |
| ONE Bio Corp. | 20.12 Million USD | -16158.029% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -8026.164% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -6691106.544% |
| Q BioMed Inc. | -8988.00 USD | 36404194.348% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -11480.251% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 21213792.946% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -7276.378% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 286722.307% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -4674185.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 66074413.409% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 3355481.223% |
| GB Sciences, Inc. | -624.00 USD | 524359074.359% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 3803512.842% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1573077023.077% |
| Enzolytics Inc. | 30.7 Thousand USD | -10655103.856% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -678128.894% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | -195.179% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 636044.88% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -529878.101% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -698.92% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 36946802.8% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 3902352.859% |
| Kadimastem Ltd | -630.13 Thousand USD | 519351.339% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -331080.458% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 27646910.308% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1853094.382% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -240994.711% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 11282858.621% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -726941.638% |
| SYBLEU INC | 11.69 Thousand USD | -27975276.197% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -70906.944% |
| Bioxytran, Inc. | -8285.00 USD | 39493159.747% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 877311.796% |
| Neutra Corp. | 14.33 Thousand USD | -22825152.878% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 3990343.902% |
| PureTech Health plc | -1.6 Million USD | 204217.28% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 326896.08% |
| IXICO plc | 3.27 Million USD | -99961.162% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 471569.741% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 182791.234% |
| CSL Limited | 7.7 Billion USD | 57.534% |
| Cellectis S.A. | 18 Thousand USD | -18177677.778% |